To update a previously published systematic literature review and meta-analysis investigating the effectiveness of asthma self-management education programs on health outcomes in children. METHODS: The updated search is through June 2010 and included published meta-analysis or journals from MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials. All available English abstracts were reviewed and the full text was consulted as necessary to clarify eligibility status. Eligible studies were randomized controlled trials or controlled clinical trials that evaluated outcomes in children ages 2-18 years with a diagnosis of asthma. Data were extracted on the study population, intervention types, sample size, sample size calculations, loss to follow-up, outcomes, and methodological quality of the studies. Data were pooled using both fixed effects and random effects models. Effect estimates were plotted in forest plots and heterogeneity was assessed visually and statistically using the I 2 statistic. All data were analyzed using OBJECTIVES: Asthma, a chronic disease requires lifelong adherence to medication and optimal self-management. Studies indicate that worldwide self-management of asthma is poor and evidence-based suitable interventions are needed for asthma control. The present study was conducted to investigate the pattern of self-management in asthmatic patients in Delhi, India. METHODS: Adult asthma patients (nϭ200) visiting emergency room (December 2008-December 2009) of a tertiary care referral chest hospital for asthma exacerbation completed self-report questionnaire on self-management of asthma after stabilization. Written informed consent from patients and ethical clearance from institute was obtained. Questionnaire contained 51 questions having six domains: Socio-demographic profile, clinical profile, morbidity and activities of living, access to care, asthma attack prevention and emergency actions. RESULTS: Study population had 64% female, 51.5% between 30-40 year and 10% were illiterate. Patients were enrolled as asthma outpatients in the study hospital for 5.4Ϯ4.4 years. All patients except one were prescribed corticosteroidϩbeta2 agonist inhalers. Patients visiting ER and having unscheduled visit to doctor at least twice in the previous 12 months were 86.5% and 91% respectively. Patients were classified according to the disease severity as having intermittent (17%) or persistent (83%) asthma. Majority of patients visited the study hospital for usual source of treatment and in case of exacerbation. Not all patients had meter dose inhalers at home. Only 2% patients were prescribed peak flow meter and one patient reported using it regularly and keeping diary. No statistical difference was found in pattern of self-management by patients having persistent or intermittent asthma. Except one, no patient had any written action plan for treatment or for emergency. CONCLUSIONS: Findings revealed poor selfmanagement of asthma and lack of communication between doctor and patient. Immediate action is needed to impart knowledge of self-management and written action plan for asthma patients by physicians. Therapy switch was defined as patient switching all drugs taken in the previous year. Probability of hospitalization was estimated using a logit model with regressors of age, gender, race, previous hospitalization, previous therapy, previous COPD test, physician visits and comorbidities. RESULTS: A total of 44,933 patients were included in the study. The average age was 77.8 years old. A majority of the patients were female (64.1%), and white (89.8%). Congestive heart failure, diabetes and hyperlipidemia were the most common comorbidities. The most frequently prescribed therapy was oxygen (around 30%), followed by Short-Acting Beta Agonists (14%). Patients who received greater COPD medical management as defined as COPD therapy (including higher OCS use), number spirometry tests and physician visits for COPD were associated with decreased likelihood of hospitalization in 2008 (p-value Ͻ 0.05). Moreover, therapy discontinuation, new therapy starters, weight loss, hyperlipidemia, liver disease, coagulapathy and renal failure were associated with higher COPD hospitalization risk while depression, congestive heart failure with lower hospitalization risk (p-values Ͻ 0.05). Also, in this population around 21% visited a specialist physician, 14% had ER visit and 20% were hospitalized for COPD in 06, 07, 08. CONCLUSIONS: The findings suggest that patients maintaining the same therapy across years and patients with greater COPD medical management are less likely to be hospitalized compared to patients with worse disease control. 01-2009.12.31) were obtained from the agency's website posting results for reimbursement determination, and Korean Ministry of Health and Welfare Affairs' drug notification on the results of price negotiation. The questionnaire consisting of negotiation guideline (article 10, 11) and satisfaction was made and used to collect responses of pharmaceutical companies' working group. The e-mail for the survey was sent out to 31 companies, survey response rate was 71%. RESULTS: Costeffectiveness (84.5%) was affecting factor of reimbursement in decision process. The lead time of reimbursement and pricing was around 12.8months. The listing price was determined as average 67% compared to application price, application price was cut by approximately 20% in decision-making of reimbursement, after that, that price was cut by approximately 17% in price negotiation process. In negotiation process, the price of reference drugs had great influence on results of negotiation. Mainly the lowest price in therapeutic area was referenced in negotiation process. Negative perceptions on process of pricing negotiation were found especially predictability of price and appreciating its value, and the needs for detailed guideline have been mentioned. CONCLUSIONS: The satisfaction of negotiation process was very negative, the reason was that Positive list system made new drugs' listing more difficult and lengthened the lead time of listing. To enhance the negotiation process, it is necessary to develop the detailed guideline on process of price negotiation.
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